Capsule drug for treating pulmonary fungal infection and preparation method of capsule drug

Abstract

The invention belongs to the technical field of traditional Chinese medicines, and aims to provide a capsule drug for treating pulmonary fungal infection according to the knowing mechanism of herbalist doctors for pulmonary fungal infection. The capsule drug is prepared from, by weight, 100-200g of honeysuckle, 60-160g of fructus forsythiae, 150-260g of houttuynia cordata, 100-160g of polygonum cuspidatum, 150-300g of reed rhizome, 50-100g of fructus arctii, 30-90g of pepperweed seeds, 100-600g of rhizoma smilacis glabrae, 50-100g of rhizoma belamcandae, 30-100g of thunberg fritillary bulb, 50-100g of perilla, 150-260g of astragalus, 50-100g of Chinese parsnip roots, 30-160g of white atractylodes rhizome, 60-160g of radix ophiopogonis, 100-160g of radix adenophorae, 15-30g of coptis chinensis, 30-90g of radix scutellariae, 20-100g of licorice, 150-500g of raw gypsum and 100-300g of radix rehmanniae. The capsule drug is a traditional Chinese medicine formula for treating both principal and secondary aspects of diseases.

Description

technical field [0001] The invention relates to the technical field of traditional Chinese medicine, in particular to a capsule medicament for treating pulmonary fungal infection, in particular to the field of capsule medicament for patients with pulmonary fungal infection and a preparation method thereof. Background technique [0002] Physicians believe that in the past 20 years, HIV infection, hematological malignancy, hematopoietic stem cell or solid organ transplantation, the use of immunosuppressants to treat autoimmune diseases, and the intervention and indwelling of various catheters in the body have caused pulmonary fungal infection (Pulmonary fungal infection). Infection) incidence increased significantly, among which bronchopulmonary candidiasis, pulmonary aspergillosis, pulmonary cryptococcosis, pulmonary mucormycosis, and pneumocystis were the most common. Because the host is in a state of immunosuppression, the onset of pulmonary fungal infection in patients is ...

AI Technical Summary

Problems solved by technology

Because the host is in an immunosuppressed state, the onset of pulmonary fungal infection in patients is usually insidious, making the diagnosis and treatment of this type of disease difficult

At present, Western medicine generally adopts antifungal treatment for such patients, but the treatment often has a narrow bactericidal spectrum, drug resistance and obvious side effects and fails to achieve satisfactory curative effect, making this disease a leading cause of organ transplant recipients. , one of the causes of death in patients with hematological malignancies and malignant tumors, and other critically ill patients